Editorial Board Member

Dr. Eliza Beal is a Surgical Oncologist on the Gastrointestinal and Neuroendocrine Oncology and Melanoma Multidisciplinary Teams at the Barbara Ann Karmanos Cancer Institute in Detroit, MI. She is also an Assistant Professor of Oncology and Surgery at Wayne State University School of Medicine. She grew up in Ann Arbor, MI and did her undergraduate studies at the University of Michigan - Ann Arbor. She attended medical school at The Ohio State University, where she also completed internship and residency in General Surgery, obtained a Masters of Medical Science, completed a Pelotonia Postdoctoral Fellowship, and completed a clinical fellowship in Complex General Surgical Oncology. Dr. Beal lives in Corktown, Detroit. Dr. Beal has extensive training in managing gastrointestinal (GI) malignancies, sarcoma, melanoma and non-melanoma skin cancers. She takes care of patients with gastrointestinal and hepato-pancreato-biliary cancers including esophagogastric, small bowel, colon, rectal, liver, pancreas, biliary and patients with sarcoma, melanoma and non-melanomatous skin cancer. Dr. Beal's current clinical research interests include access to cancer screening and care for high-risk patients. She uses a mixed methods approach to assess barriers and facilitators of access to cancer screening in populations of patients with chronic liver disease who are at high risk of developing primary liver cancer (hepatocellular carcinoma, HCC). Current areas of investigation include patient and provider perspectives, the role of health literacy in patient access to care and the impact of health literacy on HCC patient outcomes. Her past work has focused on examining the use of preoperative risk calculators in predicting operative complications; evaluating the impact of patient, provider and institutional factors on patient outcomes in transplantation; coordination of care, quality and patient safety; and the role of protective factors in hepatic ischemia reperfusion injury. Dr. Beal is also engaged in translational research in conjunction with the tumor biology and microenvironment research program at Karmanos Cancer Institute.

access to surveillance for hepatocellular carcinoma, treatment of hepatocellular carcinoma, hepatitis B virus, hepatitis C virus, cirrhosis, minimally invasive hepatectomy, systemic cancer therapy, intrahepatic cholangiocarcinoma